U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children
Go back to U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 48.93 +0.39 (0.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.54 | 52 Week High | $45.58 | |||
| Open | $48.82 | 52 Week Low | $37.82 | |||
| Day High | $49.16 | P/E | N/A | |||
| Day Low | $48.73 | EPS | $0.00 | |||
| Volume | 428,050 | |||||
